FDA Practices Under Attack
Executive Summary
After several high-profile product recalls, the US Food and Drug Administration has lately had to spend time defending itself against critics who claim the government bureau has not only become too lax in its oversight duties, but also is ignoring-or possibly suppressing-vital information about the products it approves.
You may also be interested in...
Employers Push EHRs into Wider Use
The goal of developing a nationwide system of electronic healthcare records (EHRs) for most all Americans is moving at a slower pace than some would like. But now, a group of large and influential employers has entered the picture with a plan that seems poised to change the speed and leadership of the endeavor.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.